Saskia K Klein Selected Research

Therapeutics

9/2023	Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial.
12/2020	Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial.
10/2018	Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.
3/2016	Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Saskia K Klein Research Topics

Disease

13	Multiple Myeloma 09/2023 - 03/2016
4	Disease Progression 12/2021 - 04/2013
3	Neoplasms (Cancer) 05/2024 - 04/2013
2	Aspergillosis 02/2023 - 01/2023
2	Infections 01/2023 - 10/2018
1	Cryofibrinogenemia 09/2023
1	Glomerulonephritis 09/2023
1	Paraproteinemias (Monoclonal Gammopathy) 09/2023
1	Sudden Death 09/2023
1	Polyneuropathies (Polyneuropathy) 09/2023
1	Drug-Related Side Effects and Adverse Reactions 02/2023
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2023
1	Hypertension (High Blood Pressure) 10/2021
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/2021
1	Neutropenia 10/2021
1	Lymphopenia (Lymphocytopenia) 10/2021
1	Septic Shock (Toxic Shock Syndrome) 10/2021
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021
1	Residual Neoplasm 01/2021
1	Pain (Aches) 12/2020
1	Pancreatitis 10/2018
1	Cardiomyopathies (Cardiomyopathy) 10/2018
1	Headache (Headaches) 10/2018
1	Fatigue 10/2018
1	Thrombocytopenia (Thrombopenia) 10/2018
1	Abdominal Pain (Pain, Abdominal) 10/2018
1	Chromosome Aberrations (Chromosome Abnormalities) 11/2016
1	Myocarditis (Carditis) 12/2007

Drug/Important Bio-Agent (IBA)

7	daratumumabIBA 09/2023 - 01/2019
6	Dexamethasone (Maxidex)FDA LinkGeneric 09/2023 - 01/2019
6	Thalidomide (Thalomid)FDA Link 10/2021 - 03/2016
6	Lenalidomide (CC 5013)FDA Link 01/2021 - 03/2016
4	Bortezomib (Velcade)FDA Link 10/2021 - 11/2016
3	ixazomibIBA 09/2023 - 12/2020
3	Prednisone (Sone)FDA LinkGeneric 09/2018 - 03/2016
2	Tretinoin (Retinoic Acid)FDA LinkGeneric 12/2021 - 12/2007
2	Melphalan (Alkeran)FDA LinkGeneric 10/2018 - 03/2016
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 09/2018 - 11/2016
1	Phosphotransferases (Kinase)IBA 05/2024
1	Cytochrome P-450 CYP3AIBA 05/2024
1	CryoglobulinsIBA 09/2023
1	Blood Coagulation Factors (Coagulation Factor)IBA 09/2023
1	Proteins (Proteins, Gene)FDA Link 09/2023
1	Voriconazole (Vfend)FDA LinkGeneric 02/2023
1	TriazolesIBA 01/2023
1	AzolesIBA 01/2023
1	asciminibIBA 01/2023
1	Antineoplastic Agents (Antineoplastics)IBA 01/2021
1	Complement System Proteins (Complement)IBA 12/2020
1	Interferon-alpha (Interferon Alfa)IBA 10/2018
1	Proteasome InhibitorsIBA 10/2018
1	Imatinib Mesylate (Gleevec)FDA Link 04/2013
1	Core Binding Factor Alpha 2 SubunitIBA 04/2013
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 04/2013
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 04/2013

Therapy/Procedure

6	Stem Cell Transplantation 01/2021 - 03/2016
4	Therapeutics 09/2023 - 03/2016
1	Aftercare (After-Treatment) 02/2023
1	Drug Therapy (Chemotherapy) 01/2021
1	Transplantation 12/2020
1	MP regimen 03/2016